Key Highlights

  • H1 2026 Revenue was broadly flat at £25.0 million, but gross Margin improved to 53% from 50%.
  • Cash rose to £16.0 million with no bank borrowings, supporting an ongoing share buyback programme.
  • FY2025 revenue rose around 3% to £51.6 million, with adjusted EBITDA up roughly 10% to £12.4 million.
  • A three-year agreement with Blood Centers of America opens a foothold in the largest US hemoglobin-testing network.
  • Full interim results are due 15 September 2026, expected to confirm consensus guidance of £54.7 million revenue for FY2026.

The LSE-listed diagnostics group reported broadly flat first-half revenue but wider gross margins and continued cash generation, while pressing on with an on-market share buyback funded from a debt-free Balance Sheet . Here is what the verified numbers actually show, and what investors should watch next.

EKF Diagnostics Holdings (LSE:EKF), the LSE-listed point-of-care and life sciences reagents group based in Penarth, near Cardiff, updated the market on 30 July 2026 with a first-half trading statement showing flat revenue but improving profitability and continued Shareholder returns through its buyback programme. For a company built on haemoglobin analysers, HbA1c diabetes tests and beta-hydroxybutyrate (& Beta ;-HB) reagents, the update offered a mixed but broadly reassuring picture: sales growth has stalled short term, yet the Business is generating more profit per pound of revenue and still returning cash to shareholders.

What Happened

EKF said revenue for the six months to 30 June 2026 was £25.0 million, against £25.2 million a year earlier — essentially flat. Gross margin, however, improved to 53%, up from 50% in H1 2025, and the company said adjusted EBITDA showed continued growth, though no specific first-half figure was disclosed. Cash held by the group stood at £16.0 million as at 30 June 2026, up from £15.8 million at the end of 2025, with no bank borrowings. Management said trading remained in line with expectations and reiterated it expects to hit consensus forecasts of £54.7 million revenue and £13.6 million adjusted EBITDA for the full 2026 year. Full interim results are due on 15 September 2026.

Alongside the update, EKF confirmed it had allocated £1.4 million to its buyback programme, of which £0.9 million had been deployed during the first half. The company has been a near-weekly buyer of its own stock through 2026, with RNS purchase notices appearing almost every week since January.

Why It Matters

For a small-cap diagnostics business, flat top-line growth alongside expanding margins tells a story of operational discipline rather than commercial momentum. Investors watching AIM-listed healthcare names have grown wary of firms chasing revenue growth at the expense of profitability, so EKF's margin expansion — three percentage points year-on-year — is the more significant data point here, suggesting better pricing or a richer product mix. Combined with a growing, unleveraged cash pile and an active buyback, it points to a management team prioritising Capital discipline over growth for its own sake, at a time when many small-cap peers remain cash-constrained.

Latest Financial and Operational Performance

The first-half update built on a full 2025 financial year in which EKF reported revenue of £51.6 million, up around 3% on £50.2 million in 2024, with gross margin rising to 51% from 48%. Adjusted EBITDA for 2025 rose roughly 10% to £12.4 million from £11.3 million, and operating profit increased to £7.0 million from £6.3 million. Net cash generation from operations was £11.6 million, slightly down on £12.2 million in 2024, while year-end cash stood at £15.8 million, up from £14.3 million. The board suspended dividends, prioritising organic growth Investment and Buybacks instead — the company deployed roughly £5.1 million on-market during 2025, buying back around 21.15 million shares at an average price of about 25 pence.

Point-of-Care revenue reached £33.0 million (2024: £31.4 million), with hematology growing around 5% and diabetes testing improving. Life Sciences revenue rose to £17.9 million (2024: £16.7 million), driven by β-HB sales, up roughly 10% to £13.8 million. The company sold over 16,000 analysers during the year and distributed around 90 million consumables. At its May 2026 AGM, EKF reiterated that trading remained in line with expectations, with hematology traction described as strong and β-HB sales performing above expectations.

Key Numbers

  • H1 2026 revenue: £25.0m (H1 2025: £25.2m)
  • H1 2026 gross margin: 53% (H1 2025: 50%)
  • Cash balance at 30 June 2026: £16.0m (31 December 2025: £15.8m), no bank borrowings
  • FY2025 revenue: £51.6m (FY2024: £50.2m); adjusted EBITDA: £12.4m (FY2024: £11.3m)
  • FY2025 net cash generation from operations: £11.6m
  • FY2025 share buybacks: approximately £5.1m deployed, roughly 21.15 million shares at an average 25p
  • H1 2026 buyback allocation: £1.4m, of which £0.9m deployed in the period
  • FY2026 consensus forecasts cited by the company: revenue £54.7m, adjusted EBITDA £13.6m

Growth Opportunities

EKF's stated ambition is to become the number one global provider of point-of-care hematology testing, and it has built toward that goal through commercial partnerships. In March 2026 it signed a three-year agreement with Blood Centers of America, the largest blood Supply network in the United States, covering its DiaSpect handheld hemoglobin analyser, consumables and software licensing — a foothold in what the company calls one of the world's largest addressable markets for hemoglobin testing. In April 2026 it acquired technology Assets from Beep Insights, a sports-performance app pairing wearable data with lactate and glucose tracking, extending its Lactate Scout Sport device into consumer fitness testing. The Life Sciences division's shift toward contract development and Manufacturing (CDMO) work, alongside continued β-HB reagent strength, offers a further avenue for margin-accretive growth, as does planned cuvette capacity expansion for hematology volumes.

Risks Investors Should Know

EKF continues to carry £2.1–2.4 million of cash trapped in its Russian Subsidiary owing to sanctions, a legacy exposure that remains unresolved and Illiquid . Revenue growth has essentially stalled at group level over the past two half-year periods even as margins improve, meaning the buyback and profitability gains are, for now, doing more work than Organic Sales expansion. As a small-cap AIM stock, EKF's shares can be thinly traded and sensitive to sentiment shifts. The company also changed its Chief Financial Officer in April 2026, with Helen Jones replacing the retiring Stephen Young, introducing near-term transition risk.

What to Watch Next

The next material data point is EKF's full interim results, due 15 September 2026, which should provide the first-half adjusted EBITDA figure withheld from the July update. Investors will also want to see whether the Blood Centers of America agreement and other hematology tender wins drive a return to revenue growth in the second half, and whether the buyback continues at its recent pace.

Outlook

EKF Diagnostics' latest update is one of quiet consolidation rather than dramatic expansion: flat revenue, better margins, a growing cash pile and steady share buybacks. Whether that translates into renewed growth will depend on execution against the five-year strategic plan and deals such as the BCA hematology agreement — factors the September interim results should help clarify.